Compare BNGO & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | IMNN |
|---|---|---|
| Founded | 2003 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 12.5M |
| IPO Year | 2018 | 2000 |
| Metric | BNGO | IMNN |
|---|---|---|
| Price | $1.12 | $3.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.33 | ★ $182.61 |
| AVG Volume (30 Days) | ★ 135.4K | 26.2K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.37 |
| 52 Week High | $5.50 | $9.32 |
| Indicator | BNGO | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 59.53 |
| Support Level | $1.06 | $3.53 |
| Resistance Level | $1.18 | $3.62 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 30.53 | 92.98 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).